Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Inclusion Criteria: * Written informed consent. * Subject who are HLA A2/A28 negative who have received HLA A2-mismatch liver transplant 12 months to 5 years prior to study entry. * Able and willing to use contraception. * Be on stable maintenance of immunosuppression for at least 12 weeks prior to study entry. Exclusion Criteria: * Severe cardiac, respiratory disease or any other major organ dysfunction. * Subjects with prior non-liver solid organ or hematopoietic stem cell transplant. * Known hypersensitivity to study medication ingredients, protocol defined immunosuppressive medications, or a significant allergic reaction to any drug. * Positive serology for human immunodeficiency virus (HIV), active or latent tuberculosis (TB) or other clinically active local or systemic infection. * Use of investigational agents within 3 months of screening. * Subjects with history of autoimmune disease requiring use of immunosuppression or biologics within 24 months prior to study entry. * Subject with history of malignancy in the past 5 years. * Medical or social condition that is not compatible with adequate study follow-up and any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study. * Protocol defined laboratory value for the following parameters: * Alanine aminotransferase (ALT) and either alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT), * Kidney function e.g. eGFR, * White blood cells, * Hemoglobin, * Platelets.